Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13821165 | 0.97 | ALOX12 (0.35) | PSMB8ALOX12DGKAPSMB5TDP1 | |
| SCHEMBL126873 | 0.94 | ADRA2A (0.33) | PSMB8ALOX12DGKAPSMB5TDP1 | |
| SCHEMBL13041856 | 0.94 | ADRA2A (0.33) | PSMB8ALOX12DGKAPSMB5TDP1 | |
| SCHEMBL16502332 | 0.92 | EPHX2 (0.38) | PSMB8DGKAPSMB5SMN1; SMN2ADRA2A | |
| SCHEMBL9972409 | 0.91 | DGKA (0.41) | PSMB8ALOX12DGKAPSMB5SMN1; SMN2 | |
| SCHEMBL9972406 | 0.91 | DGKA (0.37) | PSMB8ALOX12DGKAPSMB5SMN1; SMN2 | |
| SCHEMBL17637586 | 0.89 | DGKA (0.43) | PSMB8ALOX12DGKAPSMB5SMN1; SMN2 | |
| SCHEMBL141048 | 0.89 | ADRA2A (0.36) | PSMB8ALOX12DGKAPSMB5SMN1; SMN2 | |
| SCHEMBL28680314 | 0.88 | EPHX2 (0.34) | PSMB8PSMB5TDP1ADRA2AADRA1A | |
| SCHEMBL17772541 | 0.87 | ALDH1A1 (0.30) | ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB8 1933/4885ALOX12 3900/4885DGKA 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.